產(chǎn)品概述
| 產(chǎn)品名稱（Product Name） | Pumilio 1 (7B2) Rabbit Monoclonal Antibody |
| 描述（Description） | Rabbit Monoclonal Antibody |
| 宿主（Host） | Rabbit |
| 應(yīng)用（Application） | WB,IHC-P,ICC/IF,FC,IP,IF-P |
| 種屬反應(yīng)性（Reactivity） | Human,Mouse |
產(chǎn)品性能
| 偶聯(lián)物（Conjugation） | Unconjugated |
| 修飾（Modification） | Unmodified |
| 同種型（Isotype） | IgG |
| 克?。–lonality） | Monoclonal |
| 形式（Form） | Liquid |
| 存放說明（Storage） | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 儲(chǔ)存溶液（Buffer） | Supplied in 50mM Tris-Glycine(pH 7.4), 0.15M NaCl, 40%Glycerol, 0.01% New type preservative N and 0.05% BSA. |
| 純化方式（Purification） | Affinity purification |
免疫原
| 基因名（Gene Name） | PUM1 |
| 別名（Alternative Names） | HsPUM; PUM L1; Pum1; PUMH 1; PUMH; PUMH1; Pumilio1; PUML1; |
| 基因ID（Gene ID） | 9698 |
| 蛋白ID（SwissProt ID） | Q14671 |
產(chǎn)品應(yīng)用
| 稀釋比（Dilution Ratio） | WB 1:1000-1:2000, IHC-P/IF-P 1:20, ICC/IF 1:20-1:50, FCM 1:20, IP 1:20 |
| 蛋白分子量（Molecular Weight） | 127kDa |
研究背景
Mediates post-transcriptional repression of transcripts via different mechanisms: acts via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational inhibition and mRNA degradation. Sequence-specific RNA-binding protein that acts as a post- transcriptional repressor by binding the 3'-UTR of mRNA targets. Binds to an RNA consensus sequence, the Pumilio Response Element (PRE), 5'- UGUANAUA-3', that is related to the Nanos Response Element (NRE) (PubMed:21572425, PubMed:18328718, PubMed:21653694, PubMed:21397187). Mediates post-transcriptional repression of transcripts via different mechanisms: acts via direct recruitment of the CCR4-POP2-NOT deadenylase leading to translational inhibition and mRNA degradation (PubMed:22955276). Also mediates deadenylation-independent repression by promoting accessibility of miRNAs (PubMed:18776931, PubMed:20818387, PubMed:20860814, PubMed:22345517). Following growth factor stimulation, phosphorylated and binds to the 3'-UTR of CDKN1B/p27 mRNA, inducing a local conformational change that exposes miRNA-binding sites, promoting association of miR-221 and miR-222, efficient suppression of CDKN1B/p27 expression, and rapid entry to the cell cycle (PubMed:20818387). Acts as a post-transcriptional repressor of E2F3 mRNAs by binding to its 3'- UTR and facilitating miRNA regulation (PubMed:22345517, PubMed:29474920). Represses a program of genes necessary to maintain genomic stability such as key mitotic, DNA repair and DNA replication factors. Its ability to repress those target mRNAs is regulated by the lncRNA NORAD (non-coding RNA activated by DNA damage) which, due to its high abundance and multitude of PUMILIO binding sites, is able to sequester a significant fraction of PUM1 and PUM2 in the cytoplasm (PubMed:26724866). Involved in neuronal functions by regulating ATXN1 mRNA levels: acts by binding to the 3'-UTR of ATXN1 transcripts, leading to their down-regulation independently of the miRNA machinery (PubMed:25768905, PubMed:29474920). Plays a role in cytoplasmic sensing of viral infection (PubMed:25340845). In testis, acts as a post- transcriptional regulator of spermatogenesis by binding to the 3'-UTR of mRNAs coding for regulators of p53/TP53. Involved in embryonic stem cell renewal by facilitating the exit from the ground state: acts by targeting mRNAs coding for naive pluripotency transcription factors and accelerates their down-regulation at the onset of differentiation (By similarity). Binds specifically to miRNA MIR199A precursor, with PUM2, regulates miRNA MIR199A expression at a postranscriptional level (PubMed:28431233).
研究領(lǐng)域
關(guān)鍵字： PUM1 ;Pumilio;1;(7B2);Rabbit;Monoclonal;Antibody;一抗
武漢恩璣生命科技有限公司（EnkiLife）是一家深耕生命科學(xué)，專注細(xì)胞生物學(xué)和免疫學(xué)科研試劑的研發(fā)、生產(chǎn)與銷售的生物技術(shù)企業(yè)，在全球100多個(gè)國(guó)家和地區(qū)開展業(yè)務(wù)，致力于為科研工作者提供高質(zhì)量的產(chǎn)品和卓越的客戶服務(wù)，推動(dòng)生命科學(xué)的發(fā)展。
EnkiLife的產(chǎn)品線涵蓋細(xì)胞系、原代細(xì)胞、細(xì)胞培養(yǎng)基、血清、細(xì)胞檢測(cè)試劑盒、重組靶點(diǎn)蛋白、細(xì)胞因子、重組抗體、ELISA試劑盒、生化試劑盒等，并提供技術(shù)服務(wù)與定制開發(fā)，覆蓋了生命科學(xué)研究的各大關(guān)鍵領(lǐng)域，包括細(xì)胞生物學(xué)、癌癥、免疫學(xué)、神經(jīng)科學(xué)、心血管疾病、干細(xì)胞、表觀遺傳學(xué)、內(nèi)分泌、蛋白質(zhì)組學(xué)、代謝組學(xué)等，全方位滿足您的實(shí)驗(yàn)需求，讓您享受科研的樂趣！
公司現(xiàn)已建立四大技術(shù)平臺(tái)：
EnCyto?細(xì)胞培養(yǎng)及檢測(cè)平臺(tái)：擁有細(xì)胞系庫(kù)（500+）、原代細(xì)胞庫(kù)（500+）、基礎(chǔ)培養(yǎng)基和完全培養(yǎng)基（1200+）
EnkiPro?重組蛋白平臺(tái)：現(xiàn)貨產(chǎn)品2000+，可提供定制化表達(dá)服務(wù)
EnAb?重組抗體平臺(tái)：重組兔單抗（3000+），可提供定制化和標(biāo)記服務(wù)
EnKits?試劑盒開發(fā)平臺(tái)：可提供優(yōu)質(zhì)的ELISA試劑盒、配套試劑、抗體對(duì)、生化試劑盒等相關(guān)產(chǎn)品
EnkiLife在生產(chǎn)管理方面引入ISO9001質(zhì)量管理體系和信息化、自動(dòng)化的管理工具，擁有高效穩(wěn)定的交付能力，與全球知名品牌建立了緊密的合作。
EnkiLife始終堅(jiān)持以技術(shù)創(chuàng)新為驅(qū)動(dòng)，以匠心鑄就品質(zhì)，以品質(zhì)服務(wù)客戶。
我們期待與更多的全球科研工作者和企業(yè)攜手合作，共同推動(dòng)生命科學(xué)領(lǐng)域的進(jìn)步與發(fā)展。